+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Positive Modulatory Interactions of NMDA Receptor GluN1/2B Ligand Binding Domains Attenuate Antagonists Activity

Positive Modulatory Interactions of NMDA Receptor GluN1/2B Ligand Binding Domains Attenuate Antagonists Activity

Frontiers in Pharmacology 8: 229

N-methyl D-aspartate receptors (NMDAR) play crucial role in normal brain function and pathogenesis of neurodegenerative and psychiatric disorders. Functional tetra-heteromeric NMDAR contains two obligatory GluN1 subunits and two identical or different non-GluN1 subunits that include six different gene products; four GluN2 (A-D) and two GluN3 (A-B) subunits. The heterogeneity of subunit combination facilities the distinct function of NMDARs. All GluN subunits contain an extracellular N-terminal Domain (NTD) and ligand binding domain (LBD), transmembrane domain (TMD) and an intracellular C-terminal domain (CTD). Interaction between the GluN1 and co-assembling GluN2/3 subunits through the LBD has been proven crucial for defining receptor deactivation mechanisms that are unique for each combination of NMDAR. Modulating the LBD interactions has great therapeutic potential. In the present work, by amino acid point mutations and electrophysiology techniques, we have studied the role of LBD interactions in determining the effect of well-characterized pharmacological agents including agonists, competitive antagonists, and allosteric modulators. The results reveal that agonists (glycine and glutamate) potency was altered based on mutant amino acid sidechain chemistry and/or mutation site. Most antagonists inhibited mutant receptors with higher potency; interestingly, clinically used NMDAR channel blocker memantine was about three-fold more potent on mutated receptors (N521A, N521D, and K531A) than wild type receptors. These results provide novel insights on the clinical pharmacology of memantine, which is used for the treatment of mild to moderate Alzheimer's disease. In addition, these findings demonstrate the central role of LBD interactions that can be exploited to develop novel NMDAR based therapeutics.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 060107622

Download citation: RISBibTeXText

PMID: 28536523

DOI: 10.3389/fphar.2017.00229

Related references

Conformational analysis of NMDA receptor GluN1, GluN2, and GluN3 ligand-binding domains reveals subtype-specific characteristics. Structure 21(10): 1788-1799, 2013

Intersubunit interactions at putative sites of ethanol action in the M3 and M4 domains of the NMDA receptor GluN1 and GluN2B subunits. British Journal of Pharmacology 173(12): 1950-1965, 2016

Antagonists at the glycine modulatory site of the NMDA receptor reverse neurokinin-1 receptor agonist facilitation of NMDA receptor evoked activity in the rat dorsal horn. Society for Neuroscience Abstracts 21(1-3): 1373, 1995

Induction of cre recombinase activity using modified androgen receptor ligand binding domains: a sensitive assay for ligand-receptor interactions. Nucleic Acids Research 31(15): E86, 2003

Helix 1/8 interactions influence the activity of nuclear receptor ligand-binding domains. Molecular Endocrinology 17(9): 1704-1714, 2003

Ligand binding domain interface: A tipping point for pharmacological agents binding with GluN1/2A subunit containing NMDA receptors. European Journal of Pharmacology 844: 216-224, 2019

Ligand binding mapping of megalin All four ligand binding domains have sites for receptor-ligand interactions. Journal of the American Society of Nephrology 9(PROGRAM AND ABSTR ISSUE): 66A, 1998

Anticonvulsive activity of antagonists at the glycine modulatory site on the nmda receptor complex. Society for Neuroscience Abstracts 17(1-2): 1255, 1991

Novel Mode of Antagonist Binding in NMDA Receptors Revealed by the Crystal Structure of the GluN1-GluN2A Ligand-Binding Domain Complexed to NVP-AAM077. Molecular Pharmacology 92(1): 22-29, 2017

Retinoid X receptor ligand binding domains Use of mass spectrometry to study ligand/receptor interactions. Abstracts of Papers American Chemical Society 208(1-2): BIOL 37, 1994

Ligand - binding domains integrate affinity and efficacy in the NMDA receptor. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 892 2, 2003

Molecular modeling of N-terminal domains of NMDA-receptor. Study of ligand binding to N-terminal domains. Doklady. Biochemistry and Biophysics 397: 242-250, 2004

Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 36(7): 961-971, 1997

Molecular modeling of the ligand-binding domains of the NR3A and NR3B subunits of the NMDA receptor. Doklady. Biochemistry and Biophysics 389: 83-89, 2003

Molecular modeling of ligand-binding domains of NMDA receptor NR3A and NR3B subunits. Doklady Akademii Nauk 389(2): 252-258, 2003